Abstract
Chronic hepatitis B is a serious public health issue in China. The clinical management of hepatitis B is effective with the emergence of antiviral agents. The outcome of long-term therapy and nucleos(t)ide analogues stopping rules are currently unresolved issues and unmet needs. Thus, we need to pay more attention to clinical research to build large-sample and long-term follow-up cohorts and begin with the end in mind. We believe that the way to resolve the issues above will be found with the efforts of generations.